310,853 results match your criteria Leukemia and Lymphoma of the Prostate


Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.

Int J Biol Macromol 2018 Dec 3. Epub 2018 Dec 3.

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address:

Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. The acquired Janus kinase 2 (JAK2) K607N somatic mutation was detected in about 6.8% of acute myeloid leukemia (AML) patients. Read More

View Article
December 2018
2 Reads
2.858 Impact Factor

Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.

Authors:
Eden Lake

J Am Acad Dermatol 2018 Dec 3. Epub 2018 Dec 3.

Loyola University Medical Center Dermatology, 321 N La Grange Rd, La Grange Park, IL. Electronic address:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts. Read More

View Article
December 2018
4 Reads

Multiple acute ischemic strokes as the onset manifestation of acute promyelocytic leukemia.

Rom J Intern Med 2018 Dec;56(4):265-268

National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania.

Acute promyelocytic leukemia often manifests with hemorrhagic diathesis, thrombotic events being much rarer. This is the case of a 59-year-old patient with thrombotic cerebro-vascular complications as the onset manifestation of acute promyelocytic leukemia. Read More

View Article
December 2018

Initial Diagnostic Workup of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement Summary of the CAP and ASH Guideline.

J Oncol Pract 2018 Dec 6:JOP1800613. Epub 2018 Dec 6.

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; American Society of Clinical Oncology, Alexandria, VA; and Moffitt Cancer Center, Tampa, FL.

View Article
December 2018

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN-2017 in comparison with ELN-2010 in younger patients with AML has not been validated to date.

Methods: The authors performed a retrospective study on patients aged <60 years who received idarubicin plus cytarabine (IA)-based induction chemotherapy for newly diagnosed AML. Read More

View Article
December 2018

Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.

Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Hematology, Catholic Hematology Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.

Background: The sensitivity of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) versus myeloablative conditioning (MAC) allogeneic HCT by minimal residual disease (MRD) kinetics is not well established.

Methods: This study compared long-term outcomes based on MRD kinetics for 79 patients with RIC transplants and 116 patients with MAC transplants in first complete remission (CR1) after tyrosine kinase inhibitor-based chemotherapy (median follow-up, 67.1 months). Read More

View Article
December 2018
1 Read

Benzene Exposure Response and Risk of Myeloid Neoplasms in Chinese Workers: A Multicenter Case-Cohort Study.

J Natl Cancer Inst 2018 Dec 6. Epub 2018 Dec 6.

Nanchang Center for Disease Control and Prevention, Nanchang, China.

Background: There is international consensus that benzene exposure is causally related to acute myeloid leukemia (AML), and more recent evidence of association with myelodysplastic syndromes (MDS). However, there are uncertainties about the exposure response, particularly risks by time since exposure and age at exposure.

Methods: In a case-cohort study in 110 631 Chinese workers followed up during 1972-1999 we evaluated combined MDS/AML (n = 44) and chronic myeloid leukemia (n = 18). Read More

View Article
December 2018
2 Reads

Overview of non-coding mutations in chronic lymphocytic leukemia.

Mol Oncol 2018 Dec 6. Epub 2018 Dec 6.

Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia type in which the genetic alterations influencing the clinico-biological course are not entirely understood. CLL has a heterogeneous course, with some patients showing an indolent course, and others experiencing an aggressive course. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) studies identified recurrently mutated genes in CLL, and profiled its clonal evolution patterns. Read More

View Article
December 2018
1 Read

Trends in the incidence and mortality of cancer in Saudi Arabia.

Saudi Med J 2018 Dec;39(12):1259-1262

Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia. E-mail.

Objectives: To analyze the overall trends in cancer incidence and mortality in Saudi Arabia between 1990 and 2016.   Methods: Data were retrieved through a Global Burden of Disease (GBD, 2016) database (Viz Hub) that is developed by the Institute for Health Metrics and Evaluation at the University of Washington. Results: The incidence of cancer increased around 26-fold for thyroid cancer; approximately 10-fold in breast, colon, bladder and uterine cancers; 8-fold for prostate cancer; 5-fold for renal cancer; 4-fold for pancreatic and ovarian cancer; 3. Read More

View Article
December 2018
3 Reads

Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development.

Nucleosides Nucleotides Nucleic Acids 2018 Dec 6:1-8. Epub 2018 Dec 6.

a Department of Anatomy, Physiology and Biochemistry , Swedish University of Agricultural Sciences , VHC , Uppsala , Sweden.

In this study changes in thymidine kinase 1 (TK1) levels after 24 hours of Doxorubicin (Dox) exposure of CEM and MDA MB-231 cells were determined using the commercially available AroCell TK 210 ELISA test. In cell extracts, TK1 levels increased twofold with 1 µM Dox in both cell lines, while the TK1 levels in the culture media increased with 5 and 10 µM of Dox only in case of CEM cells. In conclusion, this study reveals that the TK 210 ELISA can measure changes in intra- and extracellular TK1 levels apparently related to the mechanism of cytotoxicity of anti-cancer agents. Read More

View Article
December 2018

Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.

Targeted therapy directed against rare disease-propagating leukaemic stem cells (LSCs) is a promising prospect for improving the outcome of acute myeloid leukaemia (AML) patients. Thus, distinguishing LSCs from normal haematopoietic stem and progenitor cells (HSPCs) is essential. The CLEC12A receptor has been proposed as a specific marker of LSCs, and consequently as an appealing treatment target. Read More

View Article
December 2018

Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach.

Biomater Sci 2018 Dec 6. Epub 2018 Dec 6.

Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, P.R. China and Department of Toxicology, School of Medicine and Public Health, Zhejiang University, Hangzhou 310058, P.R. China.

Aptamers are short single-stranded DNA or RNA molecules, which have recently been developed for potential broad applications such as clinical therapeutics, diagnosis and tumor-targeted drug delivery. However, the selection of specific aptamers is often unsatisfactory using the classical protein or cell-based SELEX. Herein, we modified the paired cell line approach to identify aptamers targeting leukemia cells expressing the CD33 antigen. Read More

View Article
December 2018

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease.

Case Rep Transplant 2018 4;2018:4539757. Epub 2018 Nov 4.

Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis. In preclinical and retrospective clinical studies, use of ruxolitinib was shown to reduce graft-versus-host-disease (GVHD) in allograft recipients with moderate/severe corticosteroid-dependent or refractory chronic GVHD. While the exact mechanism for action in GVHD is not yet fully understood, prospective studies are ongoing and some patients are receiving ruxolitinib in the setting of steroid refractory GVHD. Read More

View Article
November 2018

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.

Adv Hematol 2018 1;2018:2458679. Epub 2018 Nov 1.

Medical University of Varna, Varna, Bulgaria.

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Read More

View Article
November 2018

Gene expression of , , , and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.

Cancer Manag Res 2018 9;10:5573-5589. Epub 2018 Nov 9.

Department of Pharmacology, Jinnah Medical and Dental College, Karachi, Pakistan.

Purpose: Acute myeloid leukemia patients are commonly treated with cytarabine (Ara-C) and anthracyclines but the sustained remission rate is not very promising. We explored the role of drug-metabolizing enzymes and transporters in the therapeutic response.

Patients And Methods: Bone marrow and peripheral blood samples of 90 newly diagnosed acute myeloid leukemia patients treated with standard 3+7 regimen were analyzed through real-time PCR for expression of human equilibrative nucleoside transporter 1, deoxycytidine kinase, cytidine deaminase (), deoxycytidine monophosphate deaminase () and topoisomerase IIα (). Read More

View Article
November 2018
1 Read

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.

Drug Des Devel Ther 2018 12;12:3885-3898. Epub 2018 Nov 12.

Division of Haematology and Oncology, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada,

Over the past decades, survival of patients with acute lymphoblastic leukemia (ALL) has dramatically improved, but the subgroup of patients with relapsed/refractory ALL still continues to have dismal prognosis. As an emerging therapeutic approach, chimeric antigen receptor-modified T-cells (CAR-T) represent one of the few practice-changing therapies for this subgroup of patients. Originally conceived and built in Philadelphia (University of Pennsylvania), CTL019 or tisagenlecleucel, the first CAR-T approved by the US Food and Drug Administration, showed impressive results in refractory/relapsed ALL since the publication on two pediatric patients in 2013. Read More

View Article
November 2018

Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients.

Bone Marrow Transplant 2018 Dec 5. Epub 2018 Dec 5.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

This study investigated the prognostic factors in patients (n = 89) who experienced relapse and received chemotherapy plus donor leukocyte infusion (Chemo-DLI) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Patients with early relapse (< 6 vs. > 6 months after haplo-HSCT), higher bone marrow blast count before chemo-DLI (> 20% vs. Read More

View Article
December 2018
1 Read

A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.

Bone Marrow Transplant 2018 Dec 5. Epub 2018 Dec 5.

Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China.

The source of CAR T cells can be autologous (autoCAR) or allogeneic (alloCAR). The latter is seen in patients with a history of allogeneic hematopoietic stem cell transplantation, and can be either donor-derived (DD-alloCAR) or recipient-derived (RD-alloCAR). While autoCAR is activated by CAR only, alloCAR receives activation signals from both T-cell receptor (TCR) and CAR. Read More

View Article
December 2018
2 Reads

Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro.

Nat Commun 2018 Dec 5;9(1):5180. Epub 2018 Dec 5.

Department of Neurology and Pediatrics, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.

We previously demonstrated that an integrated XIST transgene can broadly repress one chromosome 21 in Down syndrome (DS) pluripotent cells. Here we address whether trisomy-silencing can normalize cell function and development sufficiently to correct cell pathogenesis, tested in an in vitro model of human fetal hematopoiesis, for which DS cellular phenotypes are best known. XIST induction in four transgenic clones reproducibly corrected over-production of megakaryocytes and erythrocytes, key to DS myeloproliferative disorder and leukemia. Read More

View Article
December 2018

Cryopreservation of primary B cells minimally influences their signaling responses.

Sci Rep 2018 Dec 5;8(1):17651. Epub 2018 Dec 5.

Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.

Phospho flow is a powerful approach to detect cell signaling aberrations, identify biomarkers and assess pharmacodynamics, and can be performed using cryopreserved samples. The effects of cryopreservation on signaling responses and the reproducibility of phospho flow measurements are however unknown in many cell systems. Here, B lymphocytes were isolated from healthy donors and patients with the B cell malignancy chronic lymphocytic leukemia and analyzed by phospho flow using phospho-specific antibodies targeting 20 different protein epitopes. Read More

View Article
December 2018

Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.

Leukemia 2018 Dec 5. Epub 2018 Dec 5.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167, Rome, Italy.

Sézary syndrome (SS) is a rare and aggressive variant of Cutaneous T-Cell Lymphoma characterized by neoplastic distribution mainly involving blood, skin, and lymph-node. Although a role of the skin microenvironment in SS pathogenesis has long been hypothesized, its function in vivo is poorly characterized. To deepen this aspect, here we compared skin to blood-derived SS cells concurrently obtained from SS patients highlighting a greater proliferation-index and a PI3K/AKT/mTORC1 pathway activation level, particularly of mTOR protein, in skin-derived-SS cells. Read More

View Article
December 2018
1 Read

Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.

Leukemia 2018 Dec 5. Epub 2018 Dec 5.

College of Pharmacy, Army Medical University, Chongqing, China.

Ars2 is a component of the nuclear cap-binding complex (CBC) that contributes to microRNA biogenesis and is required for cellular proliferation. Little is known regarding the functional role of Ars2 in cell proliferation and leukemogenesis of acute myeloid leukemia. Here, we show that the elevated expression of Ars2 was observed in acute myeloid leukemia (AML) cell lines and bone marrow samples from AML patients and was correlated with poorer overall survival. Read More

View Article
December 2018
1 Read

Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?

Leukemia 2018 Dec 5. Epub 2018 Dec 5.

Fondazione Policlinico Universitario A. Gemelli IRCCS and Istituto di Ematologia, Università Cattolica, Roma, Italy.

View Article
December 2018

Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor.

Clin Cancer Res 2018 Dec 5. Epub 2018 Dec 5.

Stem Cell Regulation, Jichi Medical University

Purpose: Lysine-specific demethylase 1 (LSD1) regulates several biological processes via the bifunctional modulation of enhancer functions. Recently, we reported that LSD1 overexpression is a founder abnormality of T-cell leukemogenesis and is maintained in fully transformed T-cell acute lymphoblastic leukemia (T-ALL) cells. On the basis of this finding, we attempted to develop novel LSD1 inhibitors effective for T-ALL with central nervous system (CNS) involvement. Read More

View Article
December 2018

A Multiplex Droplet Digital PCR Assay for Quantification of HTLV-1c DNA Proviral Load and T-Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.

J Clin Microbiol 2018 Dec 5. Epub 2018 Dec 5.

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity at The University of Melbourne, Parkville, VIC 3010, Australia.

During human T-cell leukemia virus type-1 (HTLV-1) infection the frequency of cells harboring an integrated copy of viral cDNA, the proviral load (PVL), is the main risk factor for progression of HTLV-1-associated diseases. Accurate quantification of provirus by droplet digital PCR (ddPCR) is a powerful diagnostic tool with emerging uses for monitoring viral expression. Current ddPCR techniques quantify HTLV-1 PVL in terms of whole genomic cellular material, while the main target of HTLV-1 infection is the CD4 and CD8 T-cell. Read More

View Article
December 2018
1 Read

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Blood Adv 2018 Dec;2(23):3447-3461

Department of Medicine III, Technische Universität München, Munich, Germany.

Mesenchymal stromal cells (MSCs) are crucial components of the bone marrow (BM) microenvironment essential for regulating self-renewal, survival, and differentiation of hematopoietic stem/progenitor cells (HSPCs) in the stem cell niche. MSCs are functionally altered in myelodysplastic syndromes (MDS) and exhibit an altered methylome compared with MSCs from healthy controls, thus contributing to disease progression. To determine whether MSCs are amenable to epigenetic therapy and if this affects their function, we examined growth, differentiation, and HSPC-supporting capacity of ex vivo-expanded MSCs from MDS patients in comparison with age-matched healthy controls after direct treatment in vitro with the hypomethylating agent azacitidine (AZA). Read More

View Article
December 2018
1 Read

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a median follow-up of 15·4 months (IQR 13·7-17·3), 89 (82%) of 108 assessable patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel achieved an objective response, and complete responses were noted in 63 (58%) patients. Here we report long-term activity and safety outcomes of the ZUMA-1 study. Read More

View Article
November 2018

FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.

J Oncol Pharm Pract 2018 Dec 5:1078155218817816. Epub 2018 Dec 5.

1 Princess Noorah Oncology Center, King Abdulaziz Medical City, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.

Background: Outcomes of relapsed/refractory childhood acute leukemia remain poor. We analyzed the safety/efficacy of fludarabine, cytarabine, and granulocyte colony stimulating factor, with/without idarubicin (FLAG ± IDA) as salvage therapy compared with recent published results of novel therapies.

Methods: This retrospective study included children aged 1 to 15 years with relapsed/refractory acute leukemia who received FLAG ± IDA salvage therapy from January 2000 to December 2014. Read More

View Article
December 2018

Pharmacological Inhibition of LSD1 for Cancer Treatment.

Molecules 2018 Dec 4;23(12). Epub 2018 Dec 4.

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.

Lysine-specific demethylase 1A (LSD1, also named KDM1A) is a demethylase that can remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is aberrantly expressed in many cancers, where it impedes differentiation and contributes to cancer cell proliferation, cell metastasis and invasiveness, and is associated with inferior prognosis. Pharmacological inhibition of LSD1 has been reported to significantly attenuate tumor progression in vitro and in vivo in a range of solid tumors and acute myeloid leukemia. Read More

View Article
December 2018

Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.

Comput Biol Chem 2018 Oct 29;78:133-143. Epub 2018 Oct 29.

Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China. Electronic address:

Juvenile myelomonocytic leukaemia, an aggressive myeloproliferative neoplasm, is characterized by thrombocytopenia, splenomegaly, fever and excess myelomonocytic cells. Approximately 35% of patients with JMML occur D61Y mutation in PTPN11, and it increases the activity of the protein. However, the effect of the D61Y mutation on SHP2 conformations in molecular basis is poorly understood. Read More

View Article
October 2018

Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.

J Steroid Biochem Mol Biol 2018 Nov 30. Epub 2018 Nov 30.

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, 84105 Beer Sheva, Israel. Electronic address:

Acute myeloid leukemia (AML) is one of the deadliest hematological malignancies without effective treatment for most patients. Vitamin D derivatives (VDDs) - active metabolites 1α,25-dihydroxyvitamin D (1,25D2) and 1α,25-dihydroxyvitamin D (1,25D3) and their analogs - are differentiation-inducing agents which have potential for the therapy of AML. However, calcemic toxicity of VDDs limits their clinical use at doses effective against cancer cells in vivo. Read More

View Article
November 2018
1 Read

PARTICIPATION OF VITAMIN D-UPREGULATED PROTEIN 1 (TXNIP)-ASK1-JNK1 SIGNALOSOME IN THE ENHANCEMENT OF AML CELL DEATH BY A POST-CYTOTOXIC DIFFERENTIATION REGIMEN.

J Steroid Biochem Mol Biol 2018 Nov 30. Epub 2018 Nov 30.

Department of Pathology & Laboratory Medicine, Rutgers NJ Medical School, Newark, NJ, United States. Electronic address:

Standard therapy for Acute Myeloid Leukemia (AML) is rarely curative, and several suggested improvements have had little success so far. We have reported that in an in vitro model of a potential therapeutic regimen for AML, the activity of cytarabine (AraC) is enhanced by a sequential treatment with a combination of the vitamin D2 analog Doxercalciferol (D2) and the plant-derived antioxidant carnosic acid (CA) Importantly, the enhancement occurred selectively in patient-derived AML blasts, but not in the normal bone marrow cells. We now demonstrate that TXNIP, previously known as Vitamin D up-regulated protein 1 (VDUP1) [PMID 808674] plays a part in signaling cell death (CD) in this regimen. Read More

View Article
November 2018
1 Read

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Cancer 2018 Dec 3. Epub 2018 Dec 3.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: In a proportion of patients with chronic lymphocytic leukemia (CLL), resistance to Bruton tyrosine kinase (BTK) inhibitors (BTKi) is attributed to acquired BTK/phospholipase C gamma 2 (PLCG2) mutations. However, knowledge regarding additional genetic lesions associated with BTK/PLCG2 mutations, and gene mutations in patients lacking BTK/PLCG2 mutations, is limited.

Methods: Using targeted deep sequencing, mutations in 29 genes associated with CLL and/or the BCR signaling pathway were assessed in patients with CLL who developed resistance to BTK inhibition with ibrutinib/acalabrutinib at a single institution. Read More

View Article
December 2018

HIV virological failure in a patient with human T-lymphotropic virus type 1-associated leukemia.

AIDS 2019 Jan;33(1):159-160

Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles.

View Article
January 2019

Quantification of thiopurine nucleotides in erythrocytes and clinical application to pediatric acute lymphoblastic leukemia.

Ther Drug Monit 2018 Nov 28. Epub 2018 Nov 28.

Department of Laboratory Medicine.

Introduction: Concentrations of 6-thioguanine (6TG) nucleotides and 6-methylmercaptopurine (6MMP) nucleotides in RBCs were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This assay was validated for clinical use and was applied to blood samples from patients taking mercaptopurine (6MP).

Methods: RBCs were hemolyzed and deproteinized using perchloric acid, followed by heating for the hydrolysis of nucleotides, and the resultant base was measured using LC-MS/MS. Read More

View Article
November 2018

Maternal use of hormonal contraception and risk of childhood leukaemia - Authors' reply.

Lancet Oncol 2018 Dec;19(12):e659

Virus, Lifestyle and Genes, Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark.

View Article
December 2018

Maternal use of hormonal contraception and risk of childhood leukaemia.

Lancet Oncol 2018 Dec;19(12):e658

Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY 10032, USA; Division of Epidemiology and Biostatistics, Department of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

View Article
December 2018

Maternal use of hormonal contraception and risk of childhood leukaemia.

Lancet Oncol 2018 Dec;19(12):e657

Department of Head and Neck Oncology, West China Hospital of Stomatology, State Key Laboratory of Oral Diseases, Sichuan University, Chengdu 610041, China. Electronic address:

View Article
December 2018

Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.

Leuk Lymphoma 2018 Dec 3:1-7. Epub 2018 Dec 3.

a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only treatment option for acute myeloid leukemia (AML) refractory to induction chemotherapy, with only 10-20% of patients achieving long-term survival. Certain donor genotypes may confer leukemia-clearing effects after allo-HSCT. We performed whole-exome sequencing of five pairs of the germ lines in AML patients who achieved long-term remission after allo-HSCT and in their donors, and found two significant variants: EGFR c. Read More

View Article
December 2018
1 Read

Nobiletin down-regulates c-KIT gene expression and exerts anti-leukemic effects on human acute myeloid leukemia cells.

J Agric Food Chem 2018 Dec 3. Epub 2018 Dec 3.

Nobiletin, a dietary citrus flavonoid, has been reported to possess several biological activities, such as anti-oxidant, anti-inflammatory and anti-cancer properties. The aim of this study was to investigate the anti-leukemic effects of nobiletin and its underlying mechanisms on human acute myeloid leukemia (AML) cells. We demonstrated that nobiletin (0-100 μM) significantly reduced cell viability from 100. Read More

View Article
December 2018

In Vitro Cytotoxicity of Folate-Silica-Gold Nanorods on Mouse Acute Lymphoblastic Leukemia and Spermatogonial Cells.

Cell J 2019 Apr 18;21(1):14-26. Epub 2018 Nov 18.

Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Objective: The purpose of this study was to evaluate in vitro cytotoxicity of gold nanorods (GNRs) on the viability of spermatogonial cells (SSCs) and mouse acute lymphoblastic leukemia cells (EL4s).

Materials And Methods: In this experimental study, SSCs were isolated from the neonate mice, following enzymatic digestion and differential plating. GNRs were synthesized, then modified by silica and finally conjugated with folic acid to form F-Si-GNRs. Read More

View Article

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Br J Haematol 2018 Dec 2. Epub 2018 Dec 2.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incidence of and risk factors for MH from 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Read More

View Article
December 2018

Genetic Variants Associated with Vincristine-Induced Peripheral Neuropathy in Two Populations of Children with Acute Lymphoblastic Leukemia.

Clin Pharmacol Ther 2018 Dec 3. Epub 2018 Dec 3.

Indiana Univ. School of Med, Indianapolis, IN.

Vincristine is one of the core chemotherapy agents used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, one of the major toxicities resulting from vincristine exposure is vincristine-induced peripheral neuropathy (VIPN). When VIPN results in significant morbidity, the vincristine dose may need to be reduced, thus potentially decreasing the effectiveness of treatment. Read More

View Article
December 2018

E4F1 silencing inhibits the cell growth through cell-cycle arrest in malignant transformed cells induced by hydroquinone.

J Biochem Mol Toxicol 2018 Dec 1:e22269. Epub 2018 Dec 1.

Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, China.

Hydroquinone (HQ), one of the most significant metabolic activation products of benzene in an organism, can cause hematological toxicity, such as acute myeloid leukemia. It is a clear carcinogen that can cause changes in the disorder of cell cycle and cell growth. However, its molecular mechanisms remain unclear. Read More

View Article
December 2018

Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.

Int J Hematol 2018 Dec 3. Epub 2018 Dec 3.

Department of Hematology and Oncology, Marshall University, 1400 Hal Greer Blvd, Huntington, WV, 25701, USA.

Neutropenic enterocolitis mostly affects patients with acute myeloid leukemia (AML) who get treated with intensive chemotherapy which is associated with prolonged neutropenia; its pathogenesis is not well understood and the main factors in this life-threatening condition appear to be neutropenia, mucosal injury and a weakened immune system as a consequence of intensive chemotherapeutic agents. Midostaurin in combination with chemotherapy became the standard of care for FLT3 mutant AML since its approval by the United States Food and Drug Administration (FDA) in April 2017. Anecdotally in our institution, we noticed the common occurrence of neutropenic colitis in three out of three patients who were treated with midostaurin as part of induction chemotherapy for AML. Read More

View Article
December 2018

The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.

Clin Transl Oncol 2018 Nov 30. Epub 2018 Nov 30.

Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Background: Wilms tumor 1 (WT1) gene is overexpressed in numerous cancers, including acute myeloid leukemia (AML). The alternative WT1 gene (AWT1) is generated from alternative transcription start site in the WT1 first intron and encodes an N-terminal-truncated protein lacking the repressor domain. Although WT1 overexpression is a common feature in AML, the expression levels of the AWT1 and its underlying epigenetic alterations, as well as their clinical relevance in AML remain unknown. Read More

View Article
November 2018
1 Read

Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer.

Pathol Oncol Res 2018 Nov 30. Epub 2018 Nov 30.

Department of Laboratory Diagnostics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.

Arsenic trioxide is an approved chemotheraputic agent for the treatment of acute promyelocytic leukemia (APL). Recently, numerous studies suggested that arsenic trioxide acts as anti-cancer roles in various human malignancies. However, the molecular mechanisms are not fully elucidated. Read More

View Article
November 2018